The global market for drugs to treat systemic lupus erythematosus (SLE) is expected to reach $950.2 million in 2013 and $2.6 billion in 2018, a compound annual growth rate (CAGR) of 22.4%.
This report provides:
Download Report Overview
SCOPE OF REPORT
The scope of this report focuses on the pharmaceutical segment. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the market segment’s economic environment, market factors and potential, and forecasts for 2013 to 2018. This study will be of interest to the drug industry, patients and the medical community. It will also be of interest to suppliers of products and services to this market area.
Dr. Sanjukta Bhattacharyya is the BCC Research analyst of this report. She holds a PhD in endocrinology from the University of Calcutta in India, and has more than 14 years of experience in the pharmaceutical industry, having been associated with leading pharmaceutical companies in clinical research and project management. Of note was the successful clinical development of an antimalarial new chemical entity (NCE) (Synriam), leading to its regulatory submission and transitioning to market. Synriam became the first new drug by an Indian pharmaceutical company. Sanjukta has played significant roles in various licensing deals and alliance management for NCE codevelopment between partners. Skilled in ICH/GCP guidelines and protocols, and experienced in conducting clinical trials, Sanjukta also does medical writing involving the preparation of clinical study protocols, various relevant documents, and study reports. She also has several publications in peer-reviewed journals.